Mangoceuticals stock soars due to TRT project growth

Investing.com - Mangoceuticals Inc (NASDAQ:MGRX) stock rose 70% in pre-market trading on Friday after the company reported that its $99 testosterone replacement therapy project achieved a 336% quarter-over-quarter growth, with customer acquisition costs down 54%.

The Dallas-based telemedicine company stated that since its launch in mid-December, sales of its injectable TRT treatment program have increased by 336%. This all-inclusive monthly program, priced at $99, includes doctor consultations, medical advice, laboratory testing and analysis, and prescription medications.

Operating as a telemedicine platform, MangoRx sells health and wellness products under the MangoRx and PeachesRx brands. The company said it expects TRT to become a major growth driver in the future and plans to invest in the development of injectable and oral formulations, including PRIME by MangoRx supported by Kyzatrex.

Jacob Cohen, founder and CEO of Mangoceuticals Inc, said, “We are encouraged by the initial customer demand and sales acceleration for our injectable TRT products. We believe this demonstrates the value of our innovative approach to men’s hormone health and highlights TRT as a key strategic focus for us.”

According to The Business Research Company’s “Global Testosterone Replacement Therapy Market Report,” the global TRT market is valued at approximately $2.11 billion to $2.2 billion in 2025, with an expected compound annual growth rate of about 3.9%. All MangoRx products are prescribed by licensed healthcare providers after medical evaluation and laboratory testing.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.